Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women

Syed, Farhan; Oursler, Merry Jo; Hefferanm, T. E.; Peterson, James M.; Riggs, B. Lawrence; Khosla, Sundeep

doi:10.1007/s00198-008-0574-6

Cited by 179 publications

(146 citation statements)

References 47 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…(17) In bone biopsies of 56 postmenopausal women, decreased adipocyte number and size was seen following 1 year of transdermal estradiol (n ¼ 29) compared to placebo (n ¼ 27). This study, however, did not investigate short-term changes in adipocyte parameters.…”

Section: Discussionmentioning

confidence: 97%

Short-Term Effect of Estrogen on Human Bone Marrow Fat

Limonard

Veldhuis-Vlug

Dussen

et al. 2015

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Bone marrow fat, an unique component of the bone marrow cavity increases with aging and menopause and is inversely related to bone mass. Sex steroids may be involved in the regulation of bone marrow fat, because men have higher bone marrow fat than women and clinical observations have suggested that the variation in bone marrow fat fraction is greater in premenopausal compared to postmenopausal women and men. We hypothesized that the menstrual cycle and/or estrogen affects the bone marrow fat fraction. First, we measured vertebral bone marrow fat fraction with Dixon Quantitative Chemical Shift MRI (QCSI) twice a week during 1 month in 10 regularly ovulating women. The vertebral bone marrow fat fraction increased 0.02 (95% CI, 0.00 to 0.03) during the follicular phase (p ¼ 0.033), and showed a nonsignificant decrease of 0.02 (95% CI, -0.01 to 0.04) during the luteal phase (p ¼ 0.091). To determine the effect of estrogen on bone marrow fat, we measured vertebral bone marrow fat fraction every week for 6 consecutive weeks in 6 postmenopausal women before, during, and after 2 weeks of oral 17-b estradiol treatment (2 mg/day). Bone marrow fat fraction decreased by 0.05 (95% CI, 0.01 to 0.09) from 0.48 (95% CI, 0.42 to 0.53) to 0.43 (95% CI, 0.34 to 0.51) during 17-b estradiol administration (p < 0.001) and increased again after cessation. During 17-b estradiol administration the bone formation marker procollagen type I N propeptide (P1NP) increased (p ¼ 0.034) and the bone resorption marker C-terminal crosslinking telopeptides of collagen type I (CTx) decreased (p < 0.001). In conclusion, we described the variation in vertebral bone marrow fat fraction among ovulating premenopausal women. And among postmenopausal women, we demonstrated that 17-b estradiol rapidly reduces the marrow fat fraction, suggesting that 17-b estradiol regulates bone marrow fat independent of bone mass.

show abstract

Section: Discussionmentioning

confidence: 97%

Short-Term Effect of Estrogen on Human Bone Marrow Fat

Limonard

Veldhuis-Vlug

Dussen

et al. 2015

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…DXA (Discovery DXA System; Hologic, Bedford, MA, USA) was used to measure the BMD (g/cm 2 ) of the first to fourth lumber vertebrae, femoral neck, femoral diaphysis and tibial diaphysis. The BMD of the vertebral body was measured at the baseline and at 24 months after surgery.…”

Section: Bmd Measurement By Dual-energy X-ray Absorptiometry (Dxa)mentioning

confidence: 99%

“…The functional decline of the ovaries leads to decreased estrogen levels, which triggers osteoporotic changes (2). Osteoporosis becomes a clinical issue when fragility fractures occur in weakened bones.…”

Section: Introductionmentioning

confidence: 99%

Long-term effects of ovariectomy on the properties of bone in goats

Wang

Tang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Large animal models of osteoporosis are essential for osteoporosis research. However, the time required to establish an accurate osteoporosis model is unknown. Therefore, the aim of the present study was to establish a large animal model of osteoporosis in goats. In total, 14 Chinese goats were divided into an ovariectomized (OVX, n=7) or sham-operated (SHAM, n=7) group. Vertebral bodies were used to measure the bone mineral density (BMD) prior to the ovariectomy and at 24 months after the ovariectomy. In addition, the BMD of the femoral neck, femoral diaphysis and tibial diaphysis were measured 24 months postoperatively. Bone samples from the vertebral body, femoral head and femoral neck were scanned by micro-computed tomography (CT) to visualize the trabecular and cortical microstructure. Furthermore, the vertebral body, femoral head, femoral neck and tibial diaphysis were analyzed for mechanical strength. The BMD of vertebral body of the OVX group decreased significantly (P<0.01) at 24 months after the ovariectomy when compared with the baseline measurements. Micro-CT scans of the vertebral body revealed that the bone volume fraction, trabecular number, trabecular thickness and the degree of anisotropy decreased by 37.1, 36.7, 10.5 and 16.5%, respectively (P<0.01) in the OVX group when compared with the SHAM group. Additionally, the specific bone surface and trabecular spacing significantly increased by 37.7 and 62%, respectively in the OVX group (P<0.001). Cortical bone porosity in the vertebral body and femoral neck was greater in the OVX group when compared with the SHAM group (P<0.05). In addition, mechanical testing revealed a statistically significant difference between the vertebral bodies of the OVX group and the SHAM group. In conclusion, the present study demonstrated that an ovariectomy was able to induce significant osteoporosis and deterioration of mechanical properties in the bones of goats.

show abstract

“…Эстрогены и бисфосфонаты снижают дифференцировку мСк костного мозга в адипо-циты, увеличивая одновременно остеобластогенез, с допол-нительным эффектом снижения апоптоза остеобластов [43,45]. дополнительно эффект снижения адипоцитогенеза был показан также при применении трансдермальной системы доставки эстрогенов (препарат заместительной гормональ-ной терапии) [58]. кальцитонин и селективные модуляторы эстрогеновых рецепторов не имеют доказанных эффектов на адипогенез и остеобластогенез.…”

Section: гиперкортицизмunclassified

Obesity and osteoporosis

Шишкова¹

2011

Osteopor Bone Dis

View full text Add to dashboard Cite

Osteoporosis and obesity, two disorders of body composition, are growing in prevalence. Interestingly, these diseases share several features including a genetic predisposition and a common progenitor cell. With aging, the composition of bone marrow shifts to favor the presence of adipocytes, osteoclast activity increases, and osteoblast function declines, resulting in osteoporosis. Secondary causes of osteoporosis, including diabetes mellitus, glucocorticoids, immobility and metabolic syndrome are associated with bone-marrow adiposity. Unraveling the interface between bone and fat at a molecular and cellular level is likely to lead to a better understanding of several diseases, and to the development of drugs for both osteoporosis and obesity.

show abstract

Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women

Cited by 179 publications

References 47 publications

Short-Term Effect of Estrogen on Human Bone Marrow Fat

Short-Term Effect of Estrogen on Human Bone Marrow Fat

Long-term effects of ovariectomy on the properties of bone in goats

Obesity and osteoporosis

Contact Info

Product

Resources

About